Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme (1 selected)

Guidance programme

Showing 501 to 525 of 797

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA496
Naltrexone–bupropion for managing overweight and obesityTA494
Vismodegib for treating basal cell carcinomaTA489
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxaneTA458
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumoursTA488
Sarilumab for moderate to severe rheumatoid arthritisTA485
Aflibercept for treating choroidal neovascularisationTA486
Tofacitinib for moderate to severe rheumatoid arthritisTA480
Immunosuppressive therapy for kidney transplant in adultsTA481
Immunosuppressive therapy for kidney transplant in children and young peopleTA482
Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the kneeTA477
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphomaTA478
Reslizumab for treating severe eosinophilic asthmaTA479
Cetuximab and panitumumab for previously untreated metastatic colorectal cancerTA439
Pembrolizumab for advanced melanoma not previously treated with ipilimumabTA366
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapyTA428
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumabTA357
Sorafenib for treating advanced hepatocellular carcinomaTA474
Dimethyl fumarate for treating moderate to severe plaque psoriasisTA475
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancerTA476
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neckTA473
Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal)TA468
Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal)TA469
Holoclar for treating limbal stem cell deficiency after eye burnsTA467
Pemetrexed for the maintenance treatment of non-small-cell lung cancerTA190

Results per page

  1. 10
  2. 25
  3. 50
  4. All